Product Description
A methylated tryptophan with immune checkpoint inhibitory activity. Indoximod inhibits the enzyme indoleamine 2,3-dioxygenase (IDO), which degrades the essential amino acid tryptophan, and may increase or maintain tryptophan levels important to T cell function. Tryptophan depletion is associated with immunosuppression involving T cell arrest and anergy. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/indoximod)
Mechanisms of Action: IDO1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Double Point Ventures
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Melanoma
Phase 2: Prostate Cancer|Male Breast Cancer|Melanoma|Breast Cancer|Glioblastoma|Glioma|Medulloblastoma|Ependymoma
Phase 1: Healthy Volunteers|Non-Small-Cell Lung Cancer|Kidney Diseases|Glioma|Ependymoma|Medulloblastoma|Pancreatic Cancer|Lung Cancer|Breast Cancer|Glioblastoma|Oncology Solid Tumor Unspecified|Melanoma|Brain Cancer|Gliosarcoma|Acute Myeloid Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| GCC2020 | P1 |
Recruiting |
Ependymoma|Medulloblastoma|Glioblastoma|Brain Cancer |
2026-08-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
| GCC1949 | P2 |
Recruiting |
Glioma|Glioblastoma|Ependymoma|Medulloblastoma |
2025-10-02 |
2024-11-27 |
Primary Endpoints|Treatments |
|
| 2014-003540-12 | P2 |
Terminated |
Breast Cancer |
2022-05-04 |
2022-03-13 |
Treatments |
|
| 2017-003634-93 | P3 |
Unknown status |
Melanoma |
2021-11-28 |
2022-03-13 |
Treatments |
|
| NLG2105 | P1 |
Completed |
Medulloblastoma|Ependymoma|Glioma|Brain Cancer|Glioblastoma|Gliosarcoma |
2019-12-12 |
12% |
2024-11-27 |
Primary Endpoints|Treatments |
| NLG2106 | P1 |
Completed |
Acute Myeloid Leukemia |
2019-10-25 |
12% |
2024-11-27 |
Primary Endpoints|Treatments |
| NLG2107 | P2 |
Terminated |
Melanoma |
2019-10-21 |
50% |
2020-06-06 |
|
| 2011LS109 | P2 |
Completed |
Prostate Cancer |
2018-12-12 |
2019-05-01 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
| NLG2111 | P1 |
Completed |
Healthy Volunteers |
2018-03-05 |
2019-03-22 |
Treatments |
|
| NLG2108 | P1 |
Completed |
Healthy Volunteers |
2018-01-25 |
60% |
2019-03-21 |
Treatments |
| NLG2103 | P2 |
Completed |
Melanoma |
2018-01-17 |
50% |
2020-06-06 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| NSCLS | P1 |
Terminated |
Non-Small-Cell Lung Cancer |
2017-07-17 |
50% |
2022-04-07 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| NLG2101 | P2 |
Completed |
Breast Cancer |
2016-07-01 |
2019-03-19 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
| NCI-8461 | P2 |
Completed |
Male Breast Cancer |
2014-12-01 |
2019-03-19 |
Treatments |
|
| NCI-2011-02528 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2013-08-01 |
2019-03-19 |
Treatments |
|
| D-1MT | P1 |
Terminated |
Pancreatic Cancer|Lung Cancer|Breast Cancer|Melanoma |
2012-10-01 |
2019-03-18 |
Treatments |
|
| NCI-2009-00268 | P1 |
Completed |
Kidney Diseases |
2012-07-01 |
2019-03-22 |
Treatments |